Sarah Hurt

Program: Molecular Genetics and Genomics

Current advisor: Patricia I. Dickson, MD

Undergraduate university: University of Missouri-Columbia, 2019

Enrollment year: 2019

Research summary
Adenoviral gene therapy for Mucopolysaccharidosis type I using the vascular endothelium as a cellular source

MPS I is a lysosomal storage disease that is caused by a genetic defect in the IDUA gene with limited treatment options. I am attempting to develop a treatment for MPS I using adenoviral vectors.

Graduate publications
Hurt SC, Vera MU, Le SQ, Kan SH, Bui Q, Dickson PI. 2023 Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I. Mol Genet Metab Rep, 38():101036. PMCID: PMC10761904

Hurt SC, Dickson PI, Curiel DT. 2021 Mucopolysaccharidoses type I gene therapy. J Inherit Metab Dis, 44(5):1088-98